Advert Shionogi Europe

Promotion of Fetcroja on LinkedIn

For promoting Fetcroja (cefiderocol), both before and after it received its marketing authorization, on LinkedIn, Shionogi Europe was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.

Clause 3.1 - Promoting an unlicensed medicine

Clause 9.1 - Failing to maintain high standards

Clause 26.1 - Promoting a prescription only medicine to the public

Clause 26.2 - Encouraging members of the public to ask for a specific prescription only medicine